Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial) | Zendy

Ana Milinkovic | Zendy; Paul Benn | Zendy; Alejandro ArenasPinto | Zendy; Nataliya Brima | Zendy; Andrew Copas | Zendy; Amanda Clarke | Zendy; Martin Fisher | Zendy; Gabriel Schembri | Zendy; David Hawkins | Zendy; Andy Williams | Zendy; Richard Gilson | Zendy

Open Access

Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)

Author(s) -

Ana Milinkovic,

Paul Benn,

Alejandro ArenasPinto,

Nataliya Brima,

Andrew Copas,

Amanda Clarke,

Martin Fisher,

Gabriel Schembri,

David Hawkins,

Andy Williams,

Richard Gilson

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx062

Subject(s) - maraviroc , lopinavir , emtricitabine , medicine , regimen , lopinavir/ritonavir , ritonavir , randomized controlled trial , tolerability , adverse effect , discontinuation , lamivudine , surgery , viral load , immunology , human immunodeficiency virus (hiv) , hepatitis b virus , virus , disease , covid-19 , antiretroviral therapy , infectious disease (medical specialty)

Post-exposure prophylaxis (PEP) for HIV is often poorly tolerated and not completed. Alternative PEP regimens may improve adherence and completion, aiding HIV prevention. We conducted a randomized controlled trial of a maraviroc-based PEP regimen compared with a standard-of-care regimen using ritonavir-boosted lopinavir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research